A Study to Collect Data and Blood Samples from Mayo Patients Who Have or are Suspected of Having Amyloidosis, or Their Family Members, for Future Research


About this study

The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Either has or is suspected of having or is the family member of a patient with one of the amyloidoses including, but not limited to
    • Transthyretin
    • Fibrinogen
    • Lysozyme
    • Apolipoprotein-associated
    • Lect-2
    • Serum amyloid A
    • Gelsolin
    • Beta-2 microglobulin
    • Immunoglobulin-associated 
  • Should be able to provide informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Open for enrollment

Contact information:

Ann Engebretson L.P.N.

(507) 293-1965


More information


Publications are currently not available